Taking this into account, Stephens initiated its Inovio Pharmaceuticals Inc [INO] rating to an Overweight in a research note published on May 14, 2024; the price target was $20. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who increased its forecast for the stock in late January from “a Perform” to “an Outperform”. Maxim Group also remained covering INO and has decreased its forecast on November 09, 2022 with a “Hold” recommendation from previously “Buy” rating. BofA Securities revised its rating on November 01, 2022. It rated INO as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of INO
On Tuesday, Inovio Pharmaceuticals Inc [NASDAQ:INO] saw its stock fall -8.06% to $1.71. Over the last five days, the stock has lost -10.47%. Inovio Pharmaceuticals Inc shares have fallen nearly -6.56% since the year began. Nevertheless, the stocks have fallen -85.76% over the past one year. While a 52-week high of $13.44 was reached on 01/07/25, a 52-week low of $1.42 was recorded on 04/09/25. SMA at 50 days reached $1.8316, while 200 days put it at $4.2382.
Levels Of Support And Resistance For INO Stock
The 24-hour chart illustrates a support level at 1.6467, which if violated will result in even more drops to 1.5833. On the upside, there is a resistance level at 1.8267. A further resistance level may holdings at 1.9433. The Relative Strength Index (RSI) on the 14-day chart is 42.66, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0179, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.27%. Stochastics %K at 56.83% indicates the stock is a holding.
